Crosstalk between repair pathways elicits double-strand breaks in alkylated DNA and implications for the action of temozolomide
Temozolomide (TMZ), a DNA methylating agent, is the primary chemotherapeutic drug used in glioblastoma treatment. TMZ induces mostly N-alkylation adducts (N7-methylguanine and N3-methyladenine) and some O6-methylguanine (O6mG) adducts. Current models propose that during DNA replication, thymine is i...
Main Authors: | Robert P Fuchs, Asako Isogawa, Joao A Paulo, Kazumitsu Onizuka, Tatsuro Takahashi, Ravindra Amunugama, Julien P Duxin, Shingo Fujii |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2021-07-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/69544 |
Similar Items
-
C1q/TNF‐related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma
by: Thatchawan Thanasupawat, et al.
Published: (2018-09-01) -
The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis
by: Jiahui Zhu, et al.
Published: (2022-11-01) -
Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. <i>Biomedicines</i> 2019, <i>7</i>, 69
by: Bernd Kaina
Published: (2019-11-01) -
The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer
by: Qingming Fang
Published: (2024-01-01) -
New Insights Into DNA Repair Revealed by NucS Endonucleases From Hyperthermophilic Archaea
by: Likui Zhang, et al.
Published: (2020-07-01)